FDA-Approved Drug Lifts Barrier for Immunotherapy to Fight Rare Liver Cancer, College Researchers Find
February 25, 2026
February 25, 2026
WASHINGTON, Feb. 25 (TNSjou) -- A study published in the journal Gastroenterology indicates that an existing medication may enable immunotherapy to effectively target fibrolamellar carcinoma, a rare and often fatal liver cancer affecting children and young adults. Researchers from Cornell University College of Veterinary Medicine and the University of Washington found that this cancer type rewires its environment to sequester immune T cells, preventing them from attacking the tumor.
. . .
. . .